ArticleInternational journal of nanomedicine2025
Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Programmed Synergistic Photochemotherapy and Immune Activation of Triple Negative Breast Cancer Using Anti-PD-L1 Antibody-Conjugated Multifunctional Nanocapsules.International journal of nanomedicine · 2026Article
- 3-acetyl-11-keto-Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hypoxic tumor microenvironment (TME) significantly impacts the effectiveness of various therapies on breast cancer. Conventional chemotherapeutic agents are unable to target hypoxic tumor tissue specifically, leading to reduced treatment efficacy and severe systemic toxicity. In order to improve drug targeting ability, we developed a bioactive biomotors system (MDPP@Bif) for chemoimmunotherapy against breast cancer. Utilizing the self-driving properties of the anaerobic Methods: The physicochemical properties of diverse nano-formulations were systematically characterized. In vitro anti-tumor efficacy of the MDPP@Bif biomotors was assessed through comprehensive biological evaluations, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, live/dead staining, c cellular uptake analysis, apoptosis quantification, and wound healing assays to evaluate the in vitro anti-tumor activity of the MDPP@Bif biomotors. Furthermore, the therapeutic potential of the MDPP@Bif biohybrids was validated in vivo using a murine breast cancer model by monitoring of tumor growth kinetics, body weight fluctuations, and survival outcomes. Immunofluorescence staining was also used to further validate T-cells infiltration in the tumor tissues. Results: The developed MDPP@Bif biomotors can actively colonize hypoxic tumor tissues through Bif's inherent targeting ability, releasing DOX to inhibit tumor growth. The released αPD-L1 antibody specifically binds to PD-L1, reducing immune escape and activating T cells. The concentration of DOX in tumor tissues of the MDPP@Bif group was 2.5 times higher than in tumors treated with free DOX, significantly prolonging the median survival of mice to 62 days and reducing the toxic side effects of DOX. Conclusion: The novel bacteria-propelled biomotor MDPP@Bif shows great potential in treating solid tumors through synergistic chemotherapy and immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.